Authored By: Sarah
11 Jul 2024

 Pompe Disease Drugs Market Size to grow by USD 294.7 million between 2024-2028

According to a research report “ Pompe Disease Drugs Market” by Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies) Therapy (Enzyme replacement therapy, Substrate reduction therapy, Others) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 294.7 million, at a CAGR of  4.16% during the forecast period. In the realm of healthcare, Pompe disease, a rare and complex genetic condition characterized by the deficiency of acid alpha-glucosidase, poses a significant diagnostic challenge due to its variability of symptoms and low prevalence. To address this issue, targeted educational initiatives, such as workshops, medical conferences, and awareness campaigns, are essential for enhancing the knowledge and diagnostic capabilities of healthcare professionals, including physicians, genetic counselors, and pediatricians. These efforts are instrumental in facilitating early recognition and diagnosis of Pompe disease. Furthermore, public awareness campaigns play a crucial role in informing the general population about the disease, enabling them to recognize potential symptoms and seek timely medical attention. By increasing awareness among both healthcare providers and the public, we can improve the overall management and outcomes for individuals afflicted with Pompe disease.

Browse market data tables, figures, and in-depth TOC on “Pompe Disease Drugs Market” by Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies) Therapy (Enzyme replacement therapy, Substrate reduction therapy, Others) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample

 

By Distribution Channel, the Hospital pharmacies segment is projected to dominate the market size in 2024

Enzyme replacement therapy (ERT) is a proven treatment modality in managing genetic disorders, particularly Pompe disease. This condition arises from a deficiency of the enzyme GAA, leading to the accumulation of glycogen within cells. ERT addresses this scarcity by introducing exogenous, recombinant forms of the deficient enzyme. Administered intravenously, these enzymes facilitate glycogen breakdown, preventing its harmful accumulation. By compensating for the enzyme deficiency, ERT alleviates symptoms, enhances muscle function, and significantly improves the overall quality of life for affected individuals. This foundational therapy plays a crucial role in mitigating the deleterious effects of Pompe disease.

By Therapy, Enzyme replacement therapy  segment is expected to hold the largest market size for the year 2024

Hospital pharmacies serve a vital function in the healthcare system, particularly in the distribution and dispensing of medications for Pompe disease. These pharmacies, located within hospitals, provide immediate access to essential medications for inpatients and those undergoing specialized care. The close integration of hospital pharmacies with healthcare professionals ensures seamless communication and collaboration, enabling tailored treatment plans, effective monitoring, and prompt response to any medication requirements during hospital stays. This partnership is crucial during the acute phases of Pompe disease or when close medical supervision is necessary.

North America is forecasted to hold the largest market size by region in 2024

The Pompe Disease Drugs Market represents a significant business opportunity for pharmaceutical companies, driven by the increasing diagnosis rate and demand for effective treatments. Key players in this market include Sanofi Genzyme, Amicus Therapeutics, and Wakunaga Pharmaceutical. These companies offer enzyme replacement therapies, such as Myozyme and Lumizyme, which are essential for managing symptoms and improving patient outcomes. The market is expected to grow steadily due to ongoing research and development efforts, regulatory approvals, and expanding patient populations.

The Pompe Disease Drugs Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • Amicus Therapeutics Inc.
  • Astellas Pharma Inc.
  • AVROBIO Inc.
  • Bayer AG
  • EpiVax Inc.
  • F. Hoffmann La Roche Ltd.
  • JCR Pharmaceticals Co. Ltd.
  • Johnson and Johnson
  • Maze Therapeutics Inc.
  • Sanofi SA
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

Pompe Disease, a genetic disorder caused by deficiency of the lysosomal enzyme acid alpha-glucosidase, leads to Cardiac Abnormalities and progressive muscle weakness in Infants. This condition results from Sugar accumulation in Organs and tissues, leading to Skeletal Muscle and Heart involvement. The market for Pompe Disease Drugs is witnessing significant growth due to the development of advanced therapies like Enzyme Replacement Medicines (ERMs) and Gene Therapy. Nexviazyme, an ERM by Sanofi Genzyme, and Zolgensma, a Gene Therapy by Spark Therapeutics and Genethon, are leading treatments for Pompe Disease. These therapies aim to replace the missing or deficient enzyme and correct the genetic defect. The healthcare infrastructure is evolving to support the development and delivery of these advanced therapies, with regulatory frameworks being put in place to ensure safety and efficacy. Drug Discovery in this field is progressing rapidly, driven by Medical Advancements and a better understanding of the disease mechanism. The Incidence of Pompe Disease is estimated to be around 1 in 40,000, making it a significant area of focus for pharmaceutical companies and researchers.

Market Research Overview

Pompe Disease, a genetic disorder caused by a deficiency of the enzyme Acid Alpha-Glucosidase, results in an accumulation of glycogen in organs and tissues, leading to symptoms such as muscle weakness, hypotonia, respiratory insufficiency, and cardiac abnormalities like hypertrophic cardiomyopathy. The prevalence of this genetic condition is estimated to be around 1 in 40,000, with a higher carrier frequency in certain populations. New medications like Enzyme Replacement Therapy (ERT) from companies such as Spark Therapeutics and Genethon have been developed to replace the missing enzyme, improving muscle strength and reducing activity intolerance. However, challenges in healthcare infrastructure and regulatory framework hinder widespread access to these treatments. The classic infantile form of Pompe Disease, which affects the respiratory tract and skeletal muscles, requires urgent attention in hospitals. Medical advancements continue in drug discovery, with gene therapy also being explored as a potential solution for this debilitating condition.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio